The Global PneumococcalVaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), byDistribution Channel (Hospital Pharmacies, Retail Pharmacies, and OnlinePharmacies) was valued at US$ 7,376.6 million in 2018 and is projected toexhibit a CAGR of 7.5% over the forecast period (2018 - 2026).
Healthcare facilities are looking forward toexpand their facilities with advanced technologies to create innovative andcost-effective solutions to address barriers to universal vaccination Forinstance, in April 2016, Glaxo Smith Kline (GSK) and Vodafone collaborated toprovide smartphones with an app to various healthcare facilities in northernMozambique, Africa for a period of one year. The program received funds fromGAVI and United States Agency for International Development (USAID) undermVacciNation pilot program. The app enables these healthcare facilities toreport regularly on vaccine stock levels and refrigerator temperatures, therebyimproving critical supply chain and cold chain management. Furthermore, ithelps health workers to register patients, view their vaccination histories,and also allows to send reminders to registered patients for their nextvaccination.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2295
Browse 26 Market Data Tables and32 Figures spread through 150 Pages and in-depth TOC on "PneumococcalVaccines Market, by Vaccine Type (PCV10, PCV13, and PPSV23), by DistributionChannel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) -Global Forecast to 2026"
Increasing collaborations amongkey players to develop and introduce new pneumococcal vaccines and ongoingclinical trial studies on pneumococcal vaccine are expected to drive growth ofthe pneumococcal vaccines market. For instance, in April 2018, Merck & Co,Inc. initiated two Phase III studies of PCV-15 (V114), an investigationalpolyvalent conjugate vaccine for the prevention of pneumococcal disease.Furthermore, in February 2017, Astellas Pharma Inc. and Affinivax, Inc. signedan exclusive worldwide license agreement to develop and commercialize a vaccinetargeting Streptococcus pneumoniae. This partnership would utilize Affinivax’sproprietary vaccine technology platform – Multiple Antigen Presenting System(MAPS) to develop a novel vaccine.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/pneumococcal-vaccines-market-2295
Key Takeaways of the PneumococcalVaccines Market:
The global pneumococcal vaccinesmarket is expected to witness a CAGR of 7.5% during the forecast period, owingto increasing research and development activities to introduce novel vaccines.
Increasing adoption of PCV13vaccine, especially for adult and pediatric indication, results in thevaccine’s increasing demand in various emerging economies. Therefore, thissegment is expected to account for major revenue share in pneumococcal vaccinesmarket over the forecast period. According to the United Nations Children'sFund (UNICEF), in 2016, around 74 million doses of PCV13 were supplied, with anincrease by 7.5% as compared to 2015 globally (67 million doses).
Major players operating in theglobal pneumococcal vaccines market include, Pfizer, Inc., Merck & Co.Inc., and GlaxoSmithKline plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2295
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
